HCW BiologicsHCWB +1.36%39 PB Ratio is 1.30 as of Jun. 25, 2026, which is 29% below its 10-year median of 1.83. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,233 Biotechnology companies, HCW Biologics ranks better than 76.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), HCW Biologics's share price is $1.115. HCW Biologics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.86. Hence, HCW Biologics's PB Ratio of today is 1.30.
The historical rank and industry rank for HCW Biologics's PB Ratio or its related term are showing as below:
HCWB'
s PB Ratio Range Over the Past 10 Years
Min: 0.31 Med: 1.83 Max: 7.27
Current: 1.3
During the past 7 years, HCW Biologics's highest PB Ratio was 7.27. The lowest was 0.31. And the median was 1.83.
HCWB's PB Ratio is ranked better than 76.07% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs HCWB: 1.30
During the past 3 years, the average Book Value Per Share Growth Rate was -72.80% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of HCW Biologics was -72.80% per year. The lowest was -72.80% per year. And the median was -72.80% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HCW Biologics PB Ratio Related Terms
HCW Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for HCW Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HCW Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where HCW Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
HCW Biologics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HCW Biologics (HCWB) has a PB Ratio of 1.30 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HCW Biologics and its competitors. This is 29% below median its historical median of 1.83. Over the past decade, HCW Biologics' PB Ratio has ranged from 0.31 to 7.27. According to the industry distribution chart, HCW Biologics ranks #295 out of 1233 companies in the Biotechnology industry, placing it in the top 23.9%.
Is HCW Biologics' PB Ratio too high?
HCW Biologics' current PB Ratio of 1.30 is 29% below median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 7.27. The Biotechnology industry median PB Ratio is 2.80. HCW Biologics' value of 1.30 is 53.6% below this industry median. Based on the distribution chart, HCW Biologics ranks #295 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' PB Ratio compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #295 out of 1233 companies for PB Ratio. This places HCW Biologics in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. HCW Biologics' value of 1.30 is 53.6% below this benchmark. Historically, HCW Biologics' own PB Ratio has ranged from 0.31 to 7.27 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 2.80, HCW Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCW Biologics's current PB Ratio of 1.30 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HCW Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCW Biologics's current PB Ratio is 1.30, which is 29% below median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.12 — trading 84.7% below its estimated fair value. The current PB Ratio is 1.30, which is 29% below median its 10-year median of 1.83 and 53.6% below the Biotechnology industry median of 2.80. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HCW Biologics (HCWB), the current PB Ratio is 1.30 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.12 is trading 84.7% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
PB Ratio: 1.30 (29% below median its 10-year median of 1.83)
GF Value™: $7.29 vs. price of $1.12 (84.7% below fair value)
Industry Position: 53.6% below the Biotechnology median (#295 of 1233)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
